Cancer Epidemiology最新文献_第4页

Association between blood cholesterol profile and risk of lung cancer: A meta-analysis of prospective cohort studies 血胆固醇与肺癌风险之间的关系：前瞻性队列研究的荟萃分析。

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-11-01 DOI: 10.1016/j.canep.2025.102955

Anindita Bhattacharya , Ritabrata Mitra , Ankan Bandyopadhyay , Amitabha Sengupta , Koel Chaudhury

Research findings on the relationship between blood cholesterol levels and lung cancer (LC) risk have been inconsistent, leading to inconclusive evidence regarding a definitive association. The present meta-analysis aimed to comprehensively assess the association of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) with the risk of LC, taking into consideration all relevant prospective cohort studies. Three databases (PubMed, Scopus, and Web of Science) were systematically searched from January 2005 to Dec 2024 to identify potentially relevant articles. This meta-analysis included articles reporting the hazard ratio (HR) with a 95 % confidence interval (CI) for the highest vs. lowest categories of at least one blood cholesterol component (TC, HDL-C, or LDL-C) or sufficient data to calculate the same in relation to the risk of LC. Based on the eligibility criteria, a total of 13 prospective cohort studies involving 2,718,010 individuals and 24,842 LC cases were included. The main analysis revealed a significant inverse association between HDL-C and the risk of LC (pooled HR = 0.83, 95 % CI: 0.74–0.92). No statistically significant associations were observed for TC or LDL-C in relation to LC risk. In conclusion, higher HDL-C levels appear to be significantly associated with a lower risk of LC, whereas no significant associations is evident for TC or LDL-C. Maintaining healthy HDL-C levels through a balanced diet and regular exercise may help reduce LC incidence. Nonetheless, further large-scale prospective studies with adequate adjustment for confounding and preclinical bias are warranted to ascertain the potential causality.

关于血胆固醇水平与肺癌（LC）风险之间关系的研究结果一直不一致，导致关于明确关联的证据不确凿。本荟萃分析旨在综合评估总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）与LC风险的关系，并考虑所有相关的前瞻性队列研究。从2005年1月到2024年12月，系统地检索了三个数据库（PubMed、Scopus和Web of Science），以确定潜在的相关文章。该荟萃分析纳入了报告至少一种血液胆固醇成分（TC、HDL-C或LDL-C）的最高和最低类别的风险比（HR）为95% %置信区间（CI）的文章，或足够的数据来计算与LC风险相关的风险比。根据入选标准，共纳入13项前瞻性队列研究，涉及2,718,010例个体和24,842例LC病例。主要分析显示HDL-C与LC风险呈显著负相关（合并HR = 0.83, 95 % CI: 0.74-0.92）。未观察到TC或LDL-C与LC风险有统计学意义的关联。总之，较高的HDL-C水平似乎与较低的LC风险显著相关，而对于TC或LDL-C没有明显的相关性。通过均衡饮食和定期运动保持健康的HDL-C水平可能有助于降低LC的发病率。尽管如此，有必要进一步进行大规模的前瞻性研究，充分调整混杂和临床前偏倚，以确定潜在的因果关系。

{"title":"Association between blood cholesterol profile and risk of lung cancer: A meta-analysis of prospective cohort studies","authors":"Anindita Bhattacharya , Ritabrata Mitra , Ankan Bandyopadhyay , Amitabha Sengupta , Koel Chaudhury","doi":"10.1016/j.canep.2025.102955","DOIUrl":"10.1016/j.canep.2025.102955","url":null,"abstract":"<div><div>Research findings on the relationship between blood cholesterol levels and lung cancer (LC) risk have been inconsistent, leading to inconclusive evidence regarding a definitive association. The present meta-analysis aimed to comprehensively assess the association of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) with the risk of LC, taking into consideration all relevant prospective cohort studies. Three databases (PubMed, Scopus, and Web of Science) were systematically searched from January 2005 to Dec 2024 to identify potentially relevant articles. This meta-analysis included articles reporting the hazard ratio (HR) with a 95 % confidence interval (CI) for the highest vs. lowest categories of at least one blood cholesterol component (TC, HDL-C, or LDL-C) or sufficient data to calculate the same in relation to the risk of LC. Based on the eligibility criteria, a total of 13 prospective cohort studies involving 2,718,010 individuals and 24,842 LC cases were included. The main analysis revealed a significant inverse association between HDL-C and the risk of LC (pooled HR = 0.83, 95 % CI: 0.74–0.92). No statistically significant associations were observed for TC or LDL-C in relation to LC risk. In conclusion, higher HDL-C levels appear to be significantly associated with a lower risk of LC, whereas no significant associations is evident for TC or LDL-C. Maintaining healthy HDL-C levels through a balanced diet and regular exercise may help reduce LC incidence. Nonetheless, further large-scale prospective studies with adequate adjustment for confounding and preclinical bias are warranted to ascertain the potential causality.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102955"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between sociodemographic and clinical factors and utilization of hematopoietic cell transplant in acute myeloid leukemia from 2004 to 2020 2004 - 2020年急性髓系白血病患者社会人口学、临床因素与造血细胞移植利用的关系

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-11-01 DOI: 10.1016/j.canep.2025.102952

Utsav Joshi , Aditya Ravindra , Bradley Loeffler , Uttam Bhetuwal , Shishir Acharya , Chengu Niu , Avantika Pyakuryal , Vijaya Raj Bhatt , Prajwal Dhakal

Introduction

This study investigates the influence of sociodemographic and clinical factors on the utilization of hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) between 2004 and 2020.

Methods

Patients identified from the National Cancer Database were grouped into two cohorts (2004–2010 and 2011–2019) to assess HCT trends. An additional analysis was conducted for 2020 to characterize HCT use after the onset of the COVID-19 pandemic. Logistic regression and multivariable analysis were used to estimate the influence of patient characteristics on the odds of receiving HCT.

Results

Among 67,895 AML patients, 6968 (10.3 %) underwent HCT, with usage rising from 7.2 % in 2004–13.4 % in 2019. There was a notable increase in HCT utilization among patients > 70 years (0.4 % in 2004–2010–2.5 % in 2011–2019), Black patients (4.6–7.7 %), those with public insurance (3.2–6.2 %), and individuals with higher Charlson Comorbidity Index (CCI 1: 5.3–8.2 %; CCI 2–3: 1.9–4.8 %). Younger patients exhibited a higher likelihood of receiving HCT, with usage declining significantly with age and increasing CCI. Key factors such as race, education, income, insurance status, and AML subtype were significantly associated with HCT utilization (p < 0.01). Remarkably, HCT utilization for AML remained stable at 13.1 % in 2020 amid COVID-19 pandemic, comparable to 2019.

Conclusion

The rate of HCT utilization has continued to increase over time, with notable positive trends across various demographic groups. Despite this, substantial barriers related to sociodemographic and clinical factors hinder equitable treatment access, highlighting urgent need to address these inequities to enhance patient outcomes.

前言：本研究调查了2004 - 2020年社会人口学和临床因素对急性髓性白血病（AML）患者造血细胞移植（HCT）利用的影响。方法：从国家癌症数据库中确定的患者分为两组（2004-2010年和2011-2019年），以评估HCT趋势。对2020年进行了另一项分析，以确定COVID-19大流行发生后HCT使用的特征。使用Logistic回归和多变量分析来估计患者特征对接受HCT的几率的影响。结果：在67,895例AML患者中，6968例（10.3 %）接受了HCT，使用率从2004年的7.2 %上升到2019年的13.4 %。> 70岁患者（2004-2010-2.5 - %）、黑人患者（4.6-7.7 %）、公共保险患者（3.2-6.2 %）和Charlson合病指数较高的个体（CCI 1: 5.3-8.2 %;CCI 2-3: 1.9-4.8 %）的HCT使用率显著增加。年轻患者接受HCT的可能性更高，随着年龄的增长和CCI的增加，HCT的使用率显著下降。种族、教育程度、收入、保险状况和AML亚型等关键因素与HCT使用率显著相关（p ）结论：HCT使用率随着时间的推移持续增加，在不同人口群体中呈显著的正趋势。尽管如此，与社会人口统计学和临床因素相关的重大障碍阻碍了公平获得治疗，突出表明迫切需要解决这些不平等问题，以提高患者的治疗效果。

{"title":"Association between sociodemographic and clinical factors and utilization of hematopoietic cell transplant in acute myeloid leukemia from 2004 to 2020","authors":"Utsav Joshi , Aditya Ravindra , Bradley Loeffler , Uttam Bhetuwal , Shishir Acharya , Chengu Niu , Avantika Pyakuryal , Vijaya Raj Bhatt , Prajwal Dhakal","doi":"10.1016/j.canep.2025.102952","DOIUrl":"10.1016/j.canep.2025.102952","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigates the influence of sociodemographic and clinical factors on the utilization of hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) between 2004 and 2020.</div></div><div><h3>Methods</h3><div>Patients identified from the National Cancer Database were grouped into two cohorts (2004–2010 and 2011–2019) to assess HCT trends. An additional analysis was conducted for 2020 to characterize HCT use after the onset of the COVID-19 pandemic. Logistic regression and multivariable analysis were used to estimate the influence of patient characteristics on the odds of receiving HCT.</div></div><div><h3>Results</h3><div>Among 67,895 AML patients, 6968 (10.3 %) underwent HCT, with usage rising from 7.2 % in 2004–13.4 % in 2019. There was a notable increase in HCT utilization among patients > 70 years (0.4 % in 2004–2010–2.5 % in 2011–2019), Black patients (4.6–7.7 %), those with public insurance (3.2–6.2 %), and individuals with higher Charlson Comorbidity Index (CCI 1: 5.3–8.2 %; CCI 2–3: 1.9–4.8 %). Younger patients exhibited a higher likelihood of receiving HCT, with usage declining significantly with age and increasing CCI. Key factors such as race, education, income, insurance status, and AML subtype were significantly associated with HCT utilization (p < 0.01). Remarkably, HCT utilization for AML remained stable at 13.1 % in 2020 amid COVID-19 pandemic, comparable to 2019.</div></div><div><h3>Conclusion</h3><div>The rate of HCT utilization has continued to increase over time, with notable positive trends across various demographic groups. Despite this, substantial barriers related to sociodemographic and clinical factors hinder equitable treatment access, highlighting urgent need to address these inequities to enhance patient outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102952"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A national study of lung cancer patients below 50 years: Variations in characteristics and outcomes by age 一项针对50岁以下肺癌患者的全国性研究：不同年龄的特征和结果的变化

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-31 DOI: 10.1016/j.canep.2025.102949

Katrine Kristensen , Anja Gouliaev , Torben Riis Rasmussen , Niels Lyhne Christensen

Background

Lung cancer predominantly affects the elderly. However, a small yet significant subgroup of patients below fifty years presents unique challenges in diagnosis and treatment. This study aims to describe the characteristics and outcomes of these young patients, emphasizing the need for improved diagnostic strategies and better prognostic outcomes.

Method

This national cohort study includes all patients diagnosed 2012–2023 recorded in the Danish Lung Cancer Registry. Patients below fifty years at diagnosis were categorized as young.

Results

Out of 57,325 patients a total of 1312 (2.3 %) were below fifty years at diagnosis. Young patients were more likely to be female (p = 0.006), diagnosed with adenocarcinoma (p < 0.001) and ten times more frequent anaplastic lymphoma kinase (ALK) mutated (p < 0.001). Young patients had fewer packyears (p < 0.001), better performance status (p < 0.001), lower Charlson Comorbidity index (p < 0.001), but were more frequently diagnosed in incurable disease stage, (68.0 % vs. 60.9 % p < 0.001). Adjusted OR of being diagnosed in a curable stage was 0.75 (95 %CI 0.66–0.85) for young patients, while adjusted OR for undergoing treatment with curative intent was 1.88 (1.58–2.23). Kaplan-Meier analysis indicated higher survival rates for young patients across all stages, but only marginally in stages IIIB-IV.

Conclusion

Young patients diagnosed with lung cancer are less likely to be diagnosed in a curable stage. The pathology and smoking habits differ significantly from patients above fifty years. While pending screening is important for the older population of smokers, it remains essential to consistently address the need for early diagnosis in the young population to prevent exacerbating existing disparities.

肺癌主要影响老年人。然而，一小群50岁以下的患者在诊断和治疗方面面临着独特的挑战。本研究旨在描述这些年轻患者的特征和结果，强调需要改进诊断策略和更好的预后结果。方法：本国家队列研究包括2012-2023年在丹麦肺癌登记处记录的所有确诊患者。诊断时年龄在50岁以下的患者被归类为年轻患者。结果57,325例患者中，1312例（2.3 %）诊断年龄在50岁以下。年轻患者多为女性（p = 0.006），诊断为腺癌（p <； 0.001），间变性淋巴瘤激酶（ALK）突变（p <； 0.001）发生率高10倍。年轻患者packyears较少(p & lt; 0.001),更好的性能状态(p & lt; 0.001),降低Charlson发病率指数(p & lt; 0.001),但更经常无法治愈的疾病诊断阶段,(68.0 %与60.9 % p & lt; 0.001)。年轻患者被诊断为可治愈期的调整OR为0.75(95 %CI 0.66-0.85)，而接受治疗目的的调整OR为1.88（1.58-2.23）。Kaplan-Meier分析显示，年轻患者在所有阶段的生存率都较高，但在iib - iv期只有轻微的生存率。结论年轻肺癌患者在可治愈期诊断的可能性较低。病理和吸烟习惯与50岁以上患者有显著差异。虽然待筛查对老年吸烟者很重要，但始终解决年轻人群早期诊断的需求仍然至关重要，以防止加剧现有的差距。

{"title":"A national study of lung cancer patients below 50 years: Variations in characteristics and outcomes by age","authors":"Katrine Kristensen , Anja Gouliaev , Torben Riis Rasmussen , Niels Lyhne Christensen","doi":"10.1016/j.canep.2025.102949","DOIUrl":"10.1016/j.canep.2025.102949","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer predominantly affects the elderly. However, a small yet significant subgroup of patients below fifty years presents unique challenges in diagnosis and treatment. This study aims to describe the characteristics and outcomes of these young patients, emphasizing the need for improved diagnostic strategies and better prognostic outcomes.</div></div><div><h3>Method</h3><div>This national cohort study includes all patients diagnosed 2012–2023 recorded in the Danish Lung Cancer Registry. Patients below fifty years at diagnosis were categorized as young.</div></div><div><h3>Results</h3><div>Out of 57,325 patients a total of 1312 (2.3 %) were below fifty years at diagnosis. Young patients were more likely to be female (p = 0.006), diagnosed with adenocarcinoma (p < 0.001) and ten times more frequent anaplastic lymphoma kinase (ALK) mutated (p < 0.001). Young patients had fewer packyears (p < 0.001), better performance status (p < 0.001), lower Charlson Comorbidity index (p < 0.001), but were more frequently diagnosed in incurable disease stage, (68.0 % vs. 60.9 % p < 0.001). Adjusted OR of being diagnosed in a curable stage was 0.75 (95 %CI 0.66–0.85) for young patients, while adjusted OR for undergoing treatment with curative intent was 1.88 (1.58–2.23). Kaplan-Meier analysis indicated higher survival rates for young patients across all stages, but only marginally in stages IIIB-IV.</div></div><div><h3>Conclusion</h3><div>Young patients diagnosed with lung cancer are less likely to be diagnosed in a curable stage. The pathology and smoking habits differ significantly from patients above fifty years. While pending screening is important for the older population of smokers, it remains essential to consistently address the need for early diagnosis in the young population to prevent exacerbating existing disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102949"},"PeriodicalIF":2.3,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-assessment of melanoma risk factors versus expert assessment: A systematic review of agreement 黑色素瘤风险因素的自我评估与专家评估：一项系统的协议回顾

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-31 DOI: 10.1016/j.canep.2025.102954

Lena Friederike Kopplin, Isabelle Kaiser

The number of melanoma cases has been rising over the past decades. Hence, screening is essential to provide early and effective patient management. However, screening for risk factors binds medical resources and may be conducted by patients. To evaluate the quality and validity of such a self-assessment, a systematic review of patient-expert agreement in dermatologic examinations is presented. A systematic review of studies examining participant-expert agreement on melanoma risk factors that were published until May 2025 was conducted. Included sources were retrieved from PubMed, the Web of Science Core Collection, and Scopus. Publications in languages other than English were excluded from the analysis. Of the 3562 records identified, 29 were eligible for evaluation. Six melanoma risk factors dominated the results: Typical and atypical nevi, skin phototype, freckles, hair and eye color., with typical nevi being the most frequently assessed risk factor (22 studies). Agreement is highly heterogeneous, ranging from predominantly weaker to scarcely reported substantial agreement, casting doubts on whether individuals should be tasked with self-assessment. Individual self-assessment may currently serve as a first indication of elevated melanoma risk but cannot substitute for dermatologic screening.

在过去的几十年里，黑色素瘤病例的数量一直在上升。因此，筛查对于提供早期和有效的患者管理至关重要。然而，筛查危险因素限制了医疗资源，可能由患者进行。为了评估这种自我评估的质量和有效性，提出了皮肤病检查中患者-专家协议的系统综述。对截至2025年5月发表的关于黑色素瘤风险因素的参与者-专家共识的研究进行了系统回顾。纳入的来源检索自PubMed、Web of Science Core Collection和Scopus。以英文以外语文出版的出版物不包括在分析之内。在确定的3562个记录中，有29个有资格进行评估。结果显示，6个黑色素瘤风险因素占主导地位：典型和非典型痣、皮肤光型、雀斑、头发和眼睛颜色。典型痣是最常被评估的风险因素（22项研究）。共识是高度异质的，从明显较弱到几乎没有报道的实质性共识，这让人怀疑个人是否应该承担自我评估的任务。个体自我评估目前可以作为黑色素瘤风险升高的第一个指标，但不能代替皮肤科筛查。

{"title":"Self-assessment of melanoma risk factors versus expert assessment: A systematic review of agreement","authors":"Lena Friederike Kopplin, Isabelle Kaiser","doi":"10.1016/j.canep.2025.102954","DOIUrl":"10.1016/j.canep.2025.102954","url":null,"abstract":"<div><div>The number of melanoma cases has been rising over the past decades. Hence, screening is essential to provide early and effective patient management. However, screening for risk factors binds medical resources and may be conducted by patients. To evaluate the quality and validity of such a self-assessment, a systematic review of patient-expert agreement in dermatologic examinations is presented. A systematic review of studies examining participant-expert agreement on melanoma risk factors that were published until May 2025 was conducted. Included sources were retrieved from PubMed, the Web of Science Core Collection, and Scopus. Publications in languages other than English were excluded from the analysis. Of the 3562 records identified, 29 were eligible for evaluation. Six melanoma risk factors dominated the results: Typical and atypical nevi, skin phototype, freckles, hair and eye color., with typical nevi being the most frequently assessed risk factor (22 studies). Agreement is highly heterogeneous, ranging from predominantly weaker to scarcely reported substantial agreement, casting doubts on whether individuals should be tasked with self-assessment. Individual self-assessment may currently serve as a first indication of elevated melanoma risk but cannot substitute for dermatologic screening.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102954"},"PeriodicalIF":2.3,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological trends of lymphoma in Sri Lanka: A national cancer registry study (2005–2021) 斯里兰卡淋巴瘤的流行病学趋势：一项国家癌症登记研究（2005-2021）

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-30 DOI: 10.1016/j.canep.2025.102951

Bhawani Yasassri Alvitigala, Lallindra Viranjan Gooneratne, Chandu de Silva

Background

Globally, lymphoma incidence has been steadily rising, with notable regional and gender-based variations. Understanding these trends in developing countries like Sri Lanka is essential to address cancer control strategies.

Methodology

Cancer incidence and mortality data from the National Cancer Control Program (NCCP) registries (2005–2021) were analyzed. Temporal trends in age-standardized rates (ASR) were assessed using Joinpoint Regression to estimate annual percent change (APC) and average APC (AAPC).

Results

A total of new 15,577 lymphoma cases were reported with male predominance (60 %, n = 9346) and non-Hodgkin lymphoma (NHL) being the predominant subtype (79 %, n = 9561). The overall incidence increased significantly over 16 years (AAPC: 4.1 %; p < 0.05), with a 1.4-fold rise in both sexes and a marked rise among 0–19-year-olds, exclusively post-2019 (p < 0.05). NHL incidence was highest in individuals aged ≥ 60 years, with a 2-fold rise in both gender (APC: 3.2; 95 % CI: 0.4 – 6.1; p < 0.05) during 2011–2021. Hodgkin lymphoma (HL) showed a significant 3-fold increase in females, while trends in males fluctuated, with a significant average AAPC in both sexes from 2011 to 2021 (p < 0.05). Despite the non-significant rise in female incidence across most age groups, males in 40–59 and > 60 years age groups showed a decline. A significant rise in NHL-related deaths among males (p < 0.05) was noted, with a non-significant increase in females.

Conclusions

Our findings indicate an apparent rising burden of lymphoma in Sri Lanka, particularly among males and the elderly. However, this observed increase may be partly attributable to improvements in cancer diagnostics and NCCP reporting over time. Additionally, evolving WHO classifications and their gradual adoption may also have influenced the observed trends.

背景：在全球范围内，淋巴瘤发病率稳步上升，且存在显著的区域和性别差异。了解斯里兰卡等发展中国家的这些趋势对于制定癌症控制战略至关重要。方法：分析2005-2021年国家癌症控制规划（NCCP）登记处的癌症发病率和死亡率数据。采用关节点回归评估年龄标准化率（ASR）的时间趋势，以估计年变化百分比（APC）和平均APC （AAPC）。结果：共报告新发淋巴瘤15577例，男性占多数（60 %,n = 9346），非霍奇金淋巴瘤（NHL）为优势亚型（79 %,n = 9561）。总发病率在16岁时显著增加（AAPC: 4.1 %;p  ），60岁年龄组呈下降趋势。结论：我们的研究结果表明，斯里兰卡的淋巴瘤负担明显增加，特别是在男性和老年人中。然而，观察到的这一增长可能部分归因于癌症诊断和NCCP报告的改进。此外，世卫组织分类的演变及其逐步采用也可能影响到观察到的趋势。

{"title":"Epidemiological trends of lymphoma in Sri Lanka: A national cancer registry study (2005–2021)","authors":"Bhawani Yasassri Alvitigala, Lallindra Viranjan Gooneratne, Chandu de Silva","doi":"10.1016/j.canep.2025.102951","DOIUrl":"10.1016/j.canep.2025.102951","url":null,"abstract":"<div><h3>Background</h3><div>Globally, lymphoma incidence has been steadily rising, with notable regional and gender-based variations. Understanding these trends in developing countries like Sri Lanka is essential to address cancer control strategies.</div></div><div><h3>Methodology</h3><div>Cancer incidence and mortality data from the National Cancer Control Program (NCCP) registries (2005–2021) were analyzed. Temporal trends in age-standardized rates (ASR) were assessed using Joinpoint Regression to estimate annual percent change (APC) and average APC (AAPC).</div></div><div><h3>Results</h3><div>A total of new 15,577 lymphoma cases were reported with male predominance (60 %, n = 9346) and non-Hodgkin lymphoma (NHL) being the predominant subtype (79 %, n = 9561). The overall incidence increased significantly over 16 years (AAPC: 4.1 %; p < 0.05), with a 1.4-fold rise in both sexes and a marked rise among 0–19-year-olds, exclusively post-2019 (p < 0.05). NHL incidence was highest in individuals aged ≥ 60 years, with a 2-fold rise in both gender (APC: 3.2; 95 % CI: 0.4 – 6.1; p < 0.05) during 2011–2021. Hodgkin lymphoma (HL) showed a significant 3-fold increase in females, while trends in males fluctuated, with a significant average AAPC in both sexes from 2011 to 2021 (p < 0.05). Despite the non-significant rise in female incidence across most age groups, males in 40–59 and > 60 years age groups showed a decline. A significant rise in NHL-related deaths among males (p < 0.05) was noted, with a non-significant increase in females.</div></div><div><h3>Conclusions</h3><div>Our findings indicate an apparent rising burden of lymphoma in Sri Lanka, particularly among males and the elderly. However, this observed increase may be partly attributable to improvements in cancer diagnostics and NCCP reporting over time. Additionally, evolving WHO classifications and their gradual adoption may also have influenced the observed trends.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102951"},"PeriodicalIF":2.3,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term air pollution exposure and mortality outcomes in colorectal cancer patients: Evidence from a multicenter longitudinal study 结直肠癌患者长期空气污染暴露与死亡率结局：来自多中心纵向研究的证据

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-25 DOI: 10.1016/j.canep.2025.102948

Chih-Wen Wang , Pinpin Lin , Yu-Cheng Chen , Yueh-Hsia Luo , Chih-Da Wu , Ching-Chun Li , Chun-Hung Richard Lin

Background

Limited evidence exists regarding the relationship between air pollution and all-cause mortality in colorectal cancer stratified by clinical stages.

Methods

In this retrospective cohort study, initiated in 2010, we included patients with pathologically confirmed colorectal carcinoma. Each participant's address was geocoded to the corresponding village/borough or township, for accurate matching with estimated air pollution concentrations. The risk of all-cause mortality was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models.

Results

Our study enrolled 5126 colorectal cancer patients, with a median survival time of 72.0 months. Higher exposures were associated with greater all-cause mortality: PM_2.5₅ tertile 3 vs tertile 1—HR 1.32 (95 % CI 1.14–1.52) and SO₂ tertile 3 vs tertile 1—HR 1.22 (95 % CI 1.06–1.40). Stage-stratified results showed PM_2.5 remained significant in stages 0–I (HR 1.62, 95 % CI 1.01–2.58) and III (HR 1.39, 95 % CI 1.11–1.73), whereas SO₂ was significant in stages II (HR 1.62, 95 % CI 1.03–2.53) and III (HR 1.34, 95 % CI 1.07–1.67). In multiplicative interactions, each unit increase in PM_2.5 was linked to a 1 % higher hazard (HR = 1.01; 95 % CI, 1.01–1.02), and each unit increase in SO₂ to a 5 % higher hazard (HR = 1.05; 95 % CI, 1.04–1.05). When stage was included additively, the per-unit effects were larger—7 % for PM_2.5 (HR = 1.07; 95 % CI, 1.05–1.10) and 14 % for SO₂ (HR = 1.14; 95 % CI, 1.11–1.17). Overall, pollutant levels and clinical stage jointly heightened all-cause mortality.

Conclusions

Elevated PM_2.5 and SO₂ exposures were significantly associated with higher all-cause mortality, with effect sizes varying by stage and generally stronger in stages 0–I and II–III. Clinical stage interacted both associations, and joint exposure–stage categories showed higher risks, underscoring the need to reduce pollution exposure in high-risk patients.

背景：空气污染与按临床分期分层的结直肠癌全因死亡率之间的关系证据有限。方法本回顾性队列研究始于2010年，纳入病理确诊的结直肠癌患者。每个参与者的地址都被地理编码到相应的村/区或乡镇，以便与估计的空气污染浓度准确匹配。采用Kaplan-Meier分析和Cox比例风险回归模型评估全因死亡风险。结果本研究共纳入5126例结直肠癌患者，中位生存期为72.0个月。更高的暴露与更高的全因死亡率相关：PM2.5₅tertile 3 vs tertile 1-HR 1.32（95 % CI 1.14-1.52）和SO₂tertile 3 vs tertile 1-HR 1.22（95 % CI 1.06-1.40）。分期分层结果显示，PM2.5在0-I期（HR 1.62, 95 % CI 1.01-2.58）和III期（HR 1.39, 95 % CI 1.11-1.73）仍然显著，而SO₂在II期（HR 1.62, 95 % CI 1.03-2.53）和III期（HR 1.34, 95 % CI 1.07-1.67）显著。在乘法相互作用中，PM2.5每增加一个单位，危害增加1 % (HR = 1.01; 95 % CI, 1.01 - 1.02)，二氧化硫每增加一个单位，危害增加5 % （HR = 1.05; 95 % CI, 1.04-1.05）。当附加阶段时，单位效应更大，PM2.5为7 % (HR = 1.07; 95 % CI, 1.05-1.10)，二氧化硫为14 % （HR = 1.14; 95 % CI, 1.11-1.17）。总体而言，污染物水平和临床分期共同提高了全因死亡率。结论PM2.5和SO2暴露升高与较高的全因死亡率显著相关，且不同阶段的效应大小不同，一般在0-I期和II-III期更强。临床阶段与这两种关联相互作用，联合暴露阶段类别显示出更高的风险，强调需要减少高风险患者的污染暴露。

{"title":"Long-term air pollution exposure and mortality outcomes in colorectal cancer patients: Evidence from a multicenter longitudinal study","authors":"Chih-Wen Wang , Pinpin Lin , Yu-Cheng Chen , Yueh-Hsia Luo , Chih-Da Wu , Ching-Chun Li , Chun-Hung Richard Lin","doi":"10.1016/j.canep.2025.102948","DOIUrl":"10.1016/j.canep.2025.102948","url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence exists regarding the relationship between air pollution and all-cause mortality in colorectal cancer stratified by clinical stages.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, initiated in 2010, we included patients with pathologically confirmed colorectal carcinoma. Each participant's address was geocoded to the corresponding village/borough or township, for accurate matching with estimated air pollution concentrations. The risk of all-cause mortality was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Our study enrolled 5126 colorectal cancer patients, with a median survival time of 72.0 months. Higher exposures were associated with greater all-cause mortality: PM<sub>2.5</sub>₅ tertile 3 vs tertile 1—HR 1.32 (95 % CI 1.14–1.52) and SO₂ tertile 3 vs tertile 1—HR 1.22 (95 % CI 1.06–1.40). Stage-stratified results showed PM<sub>2.5</sub> remained significant in stages 0–I (HR 1.62, 95 % CI 1.01–2.58) and III (HR 1.39, 95 % CI 1.11–1.73), whereas SO₂ was significant in stages II (HR 1.62, 95 % CI 1.03–2.53) and III (HR 1.34, 95 % CI 1.07–1.67). In multiplicative interactions, each unit increase in PM<sub>2.5</sub> was linked to a 1 % higher hazard (HR = 1.01; 95 % CI, 1.01–1.02), and each unit increase in SO₂ to a 5 % higher hazard (HR = 1.05; 95 % CI, 1.04–1.05). When stage was included additively, the per-unit effects were larger—7 % for PM<sub>2.5</sub> (HR = 1.07; 95 % CI, 1.05–1.10) and 14 % for SO₂ (HR = 1.14; 95 % CI, 1.11–1.17). Overall, pollutant levels and clinical stage jointly heightened all-cause mortality.</div></div><div><h3>Conclusions</h3><div>Elevated PM<sub>2.5</sub> and SO<sub>2</sub> exposures were significantly associated with higher all-cause mortality, with effect sizes varying by stage and generally stronger in stages 0–I and II–III. Clinical stage interacted both associations, and joint exposure–stage categories showed higher risks, underscoring the need to reduce pollution exposure in high-risk patients.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102948"},"PeriodicalIF":2.3,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence rates and trends of paediatric cancer in Italy, 2008–2017 2008-2017年意大利儿童癌症发病率和趋势

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-24 DOI: 10.1016/j.canep.2025.102947

Enrica Santelli , Gemma Gatta , Fabio Savoia , Sabrina Fabiano , Francesco Cuccaro , Viviana Perotti , Andrea Tittarelli , Tiziana Scuderi , Rosalba Amodio , Walter Mazzucco , Fabrizio Stracci , Ilaria Cozzi , AIRTUM Working Group

Background

Paediatric cancers are rare, yet, Italy has previously shown some of the highest incidence rates in Europe as a leading cause of death in children and adolescents. This study updates data from Italy for 2008–2017, analyses trends from 1998, and compares findings with other European regions.

Methods

A population-based approach was used, leveraging data from the Italian Association of Cancer Registries (AIRTUM). Thirty-one cancer registries covering 77 % of the Italian paediatric population contributed data on tumour type, age, sex, residence, and diagnosis date. Cancers were classified using the International Classification of Childhood Cancer, Third Edition (ICCC-3). Age-specific (IR) and age-standardized incidence rates (ASR) were computed, while trends were analysed with Joinpoint regression to estimate annual (APC) and average annual percentage change (AAPC).

Results

From 2008–2017, 17,322 malignant paediatric cancer cases were reported in Italy. The age-standardized incidence rate (ASR) was 166.8 per million for ages 0–14 and 294.3 per million for adolescents 15–19. Over the study period, incidence rates were generally stable, but a significant increase was observed for bone tumours in children and thyroid and melanoma in adolescents. Central Italy showed higher incidence rates compared to other Italian regions. Italy still shows one of the highest incidence rates in Europe.

Conclusion

While the study confirms overall stable incidence trends in Italy, it also highlights an increase in specific cancers such as melanoma and thyroid tumours in adolescents. Central Italy exhibited higher incidence rates, potentially due to environmental and/or diagnostic factors. Continuous monitoring and further research are needed to clarify regional variations and evaluate the impact of early diagnosis and environmental exposures.

儿童癌症是罕见的，然而，意大利以前的发病率是欧洲最高的，是儿童和青少年死亡的主要原因。这项研究更新了意大利2008-2017年的数据，分析了1998年以来的趋势，并将研究结果与其他欧洲地区进行了比较。方法采用基于人群的方法，利用意大利癌症登记协会（AIRTUM）的数据。31个癌症登记处提供了肿瘤类型、年龄、性别、居住地和诊断日期的数据，覆盖了77% 意大利儿科人口。使用国际儿童癌症分类第三版（ICCC-3）对癌症进行分类。计算年龄特异性发病率（IR）和年龄标准化发病率（ASR），并使用Joinpoint回归分析趋势，以估计年（APC）和平均年百分比变化（AAPC）。结果2008-2017年，意大利共报告小儿恶性肿瘤17322例。年龄标准化发病率（ASR） 0-14岁为166.8 /百万人，15-19岁青少年为294.3 /百万人。在研究期间，发病率总体稳定，但观察到儿童骨肿瘤和青少年甲状腺和黑色素瘤的发病率显著增加。与意大利其他地区相比，意大利中部的发病率更高。意大利仍然是欧洲发病率最高的国家之一。结论：虽然该研究证实了意大利总体稳定的发病率趋势，但它也强调了青少年中黑色素瘤和甲状腺肿瘤等特定癌症的增加。意大利中部的发病率较高，可能是由于环境和/或诊断因素。需要持续监测和进一步研究，以澄清区域差异，并评估早期诊断和环境暴露的影响。

{"title":"Incidence rates and trends of paediatric cancer in Italy, 2008–2017","authors":"Enrica Santelli , Gemma Gatta , Fabio Savoia , Sabrina Fabiano , Francesco Cuccaro , Viviana Perotti , Andrea Tittarelli , Tiziana Scuderi , Rosalba Amodio , Walter Mazzucco , Fabrizio Stracci , Ilaria Cozzi , AIRTUM Working Group","doi":"10.1016/j.canep.2025.102947","DOIUrl":"10.1016/j.canep.2025.102947","url":null,"abstract":"<div><h3>Background</h3><div>Paediatric cancers are rare, yet, Italy has previously shown some of the highest incidence rates in Europe as a leading cause of death in children and adolescents. This study updates data from Italy for 2008–2017, analyses trends from 1998, and compares findings with other European regions.</div></div><div><h3>Methods</h3><div>A population-based approach was used, leveraging data from the Italian Association of Cancer Registries (AIRTUM). Thirty-one cancer registries covering 77 % of the Italian paediatric population contributed data on tumour type, age, sex, residence, and diagnosis date. Cancers were classified using the International Classification of Childhood Cancer, Third Edition (ICCC-3). Age-specific (IR) and age-standardized incidence rates (ASR) were computed, while trends were analysed with Joinpoint regression to estimate annual (APC) and average annual percentage change (AAPC).</div></div><div><h3>Results</h3><div>From 2008–2017, 17,322 malignant paediatric cancer cases were reported in Italy. The age-standardized incidence rate (ASR) was 166.8 per million for ages 0–14 and 294.3 per million for adolescents 15–19. Over the study period, incidence rates were generally stable, but a significant increase was observed for bone tumours in children and thyroid and melanoma in adolescents. Central Italy showed higher incidence rates compared to other Italian regions. Italy still shows one of the highest incidence rates in Europe.</div></div><div><h3>Conclusion</h3><div>While the study confirms overall stable incidence trends in Italy, it also highlights an increase in specific cancers such as melanoma and thyroid tumours in adolescents. Central Italy exhibited higher incidence rates, potentially due to environmental and/or diagnostic factors. Continuous monitoring and further research are needed to clarify regional variations and evaluate the impact of early diagnosis and environmental exposures.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102947"},"PeriodicalIF":2.3,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center 疫苗诱导的乙型肝炎免疫在癌症患者中的流行：一项在一个第四系肿瘤学中心的13年分析

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-24 DOI: 10.1016/j.canep.2025.102946

Mariana Cavalheiro Magri , Victória Gonçalves de Paula , Marina Rossi de Camargo Pinto , Débora Bignotto Rosane Battaglia , Rafael de Oliveira , Gustavo Manoel Ferreira , Fátima Mitiko Tengan , Edson Abdala

Background

Hepatitis B virus reactivation may occur in cancer patients, leading to liver damage and early discontinuation of treatment. To evaluate vaccine-induced immunity to hepatitis B, this study investigated the prevalence of anti-HBs antibodies from patients with solid tumors or hematological malignancies.

Methods

All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10–99 IU/L) were evaluated by using multivariable logistic regression.

Results

A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p < 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55–7.98), female sex (OR=1.25, 95 % CI: 1.15–1.36), non-white patients (OR=1.13, 95 % CI: 1.04–1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07–1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39–1.94) and female sex (OR=1.39, 95 % CI: 1.20–1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).

Conclusions

This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.

背景：乙型肝炎病毒再激活可能发生在癌症患者中，导致肝损伤和早期停止治疗。为了评估疫苗诱导的乙型肝炎免疫，本研究调查了实体瘤或血液恶性肿瘤患者中抗乙型肝炎抗体的流行情况。方法纳入2011年至2023年在巴西圣保罗州癌症研究所（Instituto do cancer do Estado de Sao Paulo）接受抗hbc血清学检测且抗hbc结果阴性的所有癌症患者。在这些年中，通过线性回归评估了疫苗诱导的乙型肝炎免疫的流行情况。使用多变量logistic回归评估与抗- hbs存在和抗- hbs滴度相关的特征（强阳性：≥100 IU/L；弱阳性：10-99 IU/L）。结果共检查了23854例患者，其中实体瘤17249例，血液系统恶性肿瘤5114例。疫苗诱导的乙型肝炎免疫患病率为22.1% %，随着时间的推移呈显著线性增长（p <； 0.001）。疫苗诱导乙肝免疫的存在与年龄较小（OR=7.23, 95 %CI: 6.55-7.98）、女性（OR=1.25, 95 %CI: 1.15-1.36）、非白人患者（OR=1.13, 95 %CI: 1.04-1.22）和血液恶性肿瘤患者（OR=1.16, 95 %CI: 1.07-1.27）相关。此外，年龄较小（OR=1.64, 95 % CI: 1.39 - 1.94）和女性（OR=1.39, 95 % CI: 1.20-1.60）与强保护性抗hbs滴度（≥100 IU/L）相关。结论：这一发现表明，大约四分之一的癌症患者通过血清学证据显示抗HBV感染。癌症患者需要预防策略，他们可能从乙肝疫苗接种中受益。

{"title":"Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center","authors":"Mariana Cavalheiro Magri , Victória Gonçalves de Paula , Marina Rossi de Camargo Pinto , Débora Bignotto Rosane Battaglia , Rafael de Oliveira , Gustavo Manoel Ferreira , Fátima Mitiko Tengan , Edson Abdala","doi":"10.1016/j.canep.2025.102946","DOIUrl":"10.1016/j.canep.2025.102946","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis B virus reactivation may occur in cancer patients, leading to liver damage and early discontinuation of treatment. To evaluate vaccine-induced immunity to hepatitis B, this study investigated the prevalence of anti-HBs antibodies from patients with solid tumors or hematological malignancies.</div></div><div><h3>Methods</h3><div>All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10–99 IU/L) were evaluated by using multivariable logistic regression.</div></div><div><h3>Results</h3><div>A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p < 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55–7.98), female sex (OR=1.25, 95 % CI: 1.15–1.36), non-white patients (OR=1.13, 95 % CI: 1.04–1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07–1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39–1.94) and female sex (OR=1.39, 95 % CI: 1.20–1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).</div></div><div><h3>Conclusions</h3><div>This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102946"},"PeriodicalIF":2.3,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic factors of Mucoepidermoid Carcinoma within the head and neck: A NCDB analysis 头颈部黏液表皮样癌的预后因素：NCDB分析。

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-17 DOI: 10.1016/j.canep.2025.102945

Sebastian Respicio , Daniel Ryan , Christopher Bine , Stone Zhang , Peter Silberstein , Marco DiBlasi

Objectives

To characterize the prognostic profile of head and neck Mucoepidermoid Carcinoma (MEC) and correlate findings with survival and surgical likelihood.

Methods

This retrospective cohort study queried the National Cancer Database from 2004 to 2021 for all head and neck structures with histologically confirmed MEC. Using SPSS and GraphPad Prism, statistical analyses were conducted via Kaplan Meier Survival with Log-Rank Pairwise Comparisons, Cox Proportional Hazards Regressions, and Binomial and Multinomial Logistic Regressions.

Results

A total of 17,713 patients were included. Significant findings include worsened overall survival (OS) and hazard ratios (HR) in relation to male sex, white race, non-Hispanic ethnicity, non-Private Insurances, non-Academic/Research treatment facilities, and not undergoing surgery. MEC in the Gum & Other Mouth and in the Lip had better OS and HR while MEC of the Nose, Nasal Cavity, & Middle Ear, MEC of the Tongue, and MEC of the Pharynx had worsened OS and HR in comparison to Salivary Gland MEC. Gum & Other Mouth MEC patients had significantly increased likelihood for Local Tumor Excision and Partial Organ Removal surgeries. Tongue MEC had significantly increased likelihood for Partial Organ Removal. Nose, Nasal Cavity, & Middle Ear MEC and Pharynx MEC had significantly decreased likelihoods for Local Tumor Excision or Total/Radical Organ Removal Surgeries.

Conclusion

By identifying key determinants of survival and surgical likelihood, this work provides valuable clinical insight into patient management and outcomes for a clinically significant malignancy. Additionally, this study comments on the role of accessible surgical care and social determinants of health regarding MEC.

目的：探讨头颈部黏液表皮样癌（MEC）的预后特征，并将其与生存和手术可能性联系起来。方法：这项回顾性队列研究查询了2004年至2021年国家癌症数据库中所有组织学证实的MEC头颈部结构。使用SPSS和GraphPad Prism进行Kaplan Meier生存分析，采用Log-Rank两两比较、Cox比例风险回归、二项和多项Logistic回归进行统计分析。结果：共纳入17713例患者。重要的发现包括与男性、白人、非西班牙裔、非私人保险、非学术/研究治疗设施和未接受手术相关的总生存率（OS）和风险比（HR）恶化。与唾液腺MEC相比，牙龈及其他口腔和唇部MEC的OS和HR较好，而鼻、鼻腔和中耳MEC、舌部MEC和咽部MEC的OS和HR较差。牙龈和其他口腔MEC患者进行局部肿瘤切除和部分器官切除手术的可能性显著增加。舌MEC明显增加部分器官切除的可能性。鼻、鼻腔、中耳MEC和咽MEC进行局部肿瘤切除或全/根治性器官切除手术的可能性显著降低。结论：通过确定生存和手术可能性的关键决定因素，这项工作为临床显著恶性肿瘤的患者管理和结果提供了有价值的临床见解。此外，本研究还评论了外科护理的可及性和MEC健康的社会决定因素的作用。

{"title":"Prognostic factors of Mucoepidermoid Carcinoma within the head and neck: A NCDB analysis","authors":"Sebastian Respicio , Daniel Ryan , Christopher Bine , Stone Zhang , Peter Silberstein , Marco DiBlasi","doi":"10.1016/j.canep.2025.102945","DOIUrl":"10.1016/j.canep.2025.102945","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize the prognostic profile of head and neck Mucoepidermoid Carcinoma (MEC) and correlate findings with survival and surgical likelihood.</div></div><div><h3>Methods</h3><div>This retrospective cohort study queried the National Cancer Database from 2004 to 2021 for all head and neck structures with histologically confirmed MEC. Using SPSS and GraphPad Prism, statistical analyses were conducted via Kaplan Meier Survival with Log-Rank Pairwise Comparisons, Cox Proportional Hazards Regressions, and Binomial and Multinomial Logistic Regressions.</div></div><div><h3>Results</h3><div>A total of 17,713 patients were included. Significant findings include worsened overall survival (OS) and hazard ratios (HR) in relation to male sex, white race, non-Hispanic ethnicity, non-Private Insurances, non-Academic/Research treatment facilities, and not undergoing surgery. MEC in the Gum & Other Mouth and in the Lip had better OS and HR while MEC of the Nose, Nasal Cavity, & Middle Ear, MEC of the Tongue, and MEC of the Pharynx had worsened OS and HR in comparison to Salivary Gland MEC. Gum & Other Mouth MEC patients had significantly increased likelihood for Local Tumor Excision and Partial Organ Removal surgeries. Tongue MEC had significantly increased likelihood for Partial Organ Removal. Nose, Nasal Cavity, & Middle Ear MEC and Pharynx MEC had significantly decreased likelihoods for Local Tumor Excision or Total/Radical Organ Removal Surgeries.</div></div><div><h3>Conclusion</h3><div>By identifying key determinants of survival and surgical likelihood, this work provides valuable clinical insight into patient management and outcomes for a clinically significant malignancy. Additionally, this study comments on the role of accessible surgical care and social determinants of health regarding MEC.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102945"},"PeriodicalIF":2.3,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A cross-sectional assessment of US cancer diagnoses during the COVID-19 pandemic COVID-19大流行期间美国癌症诊断的横断面评估

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2025-10-17 DOI: 10.1016/j.canep.2025.102944

Todd Burus , Uriel Kim , Johnie Rose , Siran M. Koroukian , Krystle A. Lang Kuhs

Background

Disruptions to cancer diagnoses were widely reported in the US during the early COVID-19 pandemic. Whether any cases remained unaccounted-for by the end of the pandemic has not been fully assessed.

Methods

We collected data on invasive cancer diagnoses occurring among individuals aged 20–89 years between January 2020 and December 2022 from the Surveillance, Epidemiology, and End Results database. Expected cancer case counts and incidence rates with 95 % credibility intervals (95 %CrIs) were estimated for 2020–2022 from pre-pandemic trends (2005–2019) using Bayesian Age-Period-Cohort models. We compared observed rates with expected rates, and estimated unaccounted-for cases. Additional site-, stage-, and subgroup-specific analyses were performed.

Results

Among 2260,704 cancer cases diagnosed in 2020–2022, the observed incidence rate was 595.5 per 100,000 persons (95 %CI, 594.7–596.2), which was 6.7 % lower than the expected rate of 638.1 (95 %CrI, 620.1–656.1) and corresponded to 160,475 fewer-than-expected cases (95 %CrI, 99,777–221,174). Annual observed rates were significantly lower than expected in 2020 (565.8 vs. 630.7), with recovery in 2021 and 2022, though not enough to overcome the existing case deficit. Incidence rates for persons aged ≥ 65 years, nonmetropolitan residents, and non-Hispanic White individuals, as well as site-specific rates for lung and kidney cancers and non-Hodgkin lymphoma, remained below expected levels beyond 2020. Early-stage colorectal cancer diagnoses were 14.2 % lower than expected over the period.

Conclusion

While annual cancer incidence rates returned to expected levels by the end of the COVID-19 pandemic, substantial numbers of unaccounted-for cases remained, raising concerns for future increases in cancer morbidity and mortality.

背景：在COVID-19早期大流行期间，美国广泛报道了癌症诊断中断。尚未充分评估到大流行结束时是否仍有病例下落不明。方法：我们从监测、流行病学和最终结果数据库中收集了2020年1月至2022年12月期间20-89岁人群中浸润性癌症诊断的数据。根据大流行前趋势（2005-2019年），使用贝叶斯年龄-时期-队列模型估计了2020-2022年的预期癌症病例数和发病率，可信区间为95% %（95% %CrIs）。我们比较了观察到的发病率和预期的发病率，并估计了未解释的病例。进行了额外的部位、阶段和亚组特异性分析。结果：在2020-2022年确诊的2260704例癌症患者中，观察到的发病率为595.5 / 10万人（95 %CI, 594.7 ~ 596.2），比预期的638.1（95 %CrI, 620.1 ~ 656.1）低6.7 %，比预期少160475例（95 %CrI, 99777 ~ 221174）。2020年的年度观察率明显低于预期（565.8比630.7），2021年和2022年将有所复苏，但不足以克服现有的病例赤字。年龄≥ 65岁、非都市居民和非西班牙裔白人的发病率，以及肺癌、肾癌和非霍奇金淋巴瘤的部位特异性发病率，在2020年后仍低于预期水平。早期结直肠癌的诊断率为14.2% %，低于预期。结论：虽然到2019冠状病毒病大流行结束时，年癌症发病率已恢复到预期水平，但仍有大量不明病例存在，这引起了人们对未来癌症发病率和死亡率上升的担忧。

{"title":"A cross-sectional assessment of US cancer diagnoses during the COVID-19 pandemic","authors":"Todd Burus , Uriel Kim , Johnie Rose , Siran M. Koroukian , Krystle A. Lang Kuhs","doi":"10.1016/j.canep.2025.102944","DOIUrl":"10.1016/j.canep.2025.102944","url":null,"abstract":"<div><h3>Background</h3><div>Disruptions to cancer diagnoses were widely reported in the US during the early COVID-19 pandemic. Whether any cases remained unaccounted-for by the end of the pandemic has not been fully assessed.</div></div><div><h3>Methods</h3><div>We collected data on invasive cancer diagnoses occurring among individuals aged 20–89 years between January 2020 and December 2022 from the Surveillance, Epidemiology, and End Results database. Expected cancer case counts and incidence rates with 95 % credibility intervals (95 %CrIs) were estimated for 2020–2022 from pre-pandemic trends (2005–2019) using Bayesian Age-Period-Cohort models. We compared observed rates with expected rates, and estimated unaccounted-for cases. Additional site-, stage-, and subgroup-specific analyses were performed.</div></div><div><h3>Results</h3><div>Among 2260,704 cancer cases diagnosed in 2020–2022, the observed incidence rate was 595.5 per 100,000 persons (95 %CI, 594.7–596.2), which was 6.7 % lower than the expected rate of 638.1 (95 %CrI, 620.1–656.1) and corresponded to 160,475 fewer-than-expected cases (95 %CrI, 99,777–221,174). Annual observed rates were significantly lower than expected in 2020 (565.8 vs. 630.7), with recovery in 2021 and 2022, though not enough to overcome the existing case deficit. Incidence rates for persons aged ≥ 65 years, nonmetropolitan residents, and non-Hispanic White individuals, as well as site-specific rates for lung and kidney cancers and non-Hodgkin lymphoma, remained below expected levels beyond 2020. Early-stage colorectal cancer diagnoses were 14.2 % lower than expected over the period.</div></div><div><h3>Conclusion</h3><div>While annual cancer incidence rates returned to expected levels by the end of the COVID-19 pandemic, substantial numbers of unaccounted-for cases remained, raising concerns for future increases in cancer morbidity and mortality.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102944"},"PeriodicalIF":2.3,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145319004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0